← Back to Search

Partial Dopamine Agonist

1 for Schizophrenia

Phase 2
Waitlist Available
Led By Thomas P Beresford, MD
Research Sponsored by Paul Saenger
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up end of study participation
Awards & highlights

Study Summary

The purpose of this study is to gather systematic clinical data on whether aripiprazole, a partial dopamine agonist, beneficially affects schizophrenia plus cocaine dependence subjects. Since aripiprazole has established effects against schizophrenia, the study focuses on whether aripiprazole concurrently reduces co-morbid cocaine dependence in schizophrenia plus cocaine dependence sufferers compared to a standard typical antipsychotic treatment (perphenazine). The working hypothesis states that subjects in the aripiprazole treatment arm of the study will give fewer cocaine positive urine specimens as compared to the perphenazine control arm.

Eligible Conditions
  • Schizophrenia
  • Cocaine Dependence

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 3 and week 8 of study participation
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 3 and week 8 of study participation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The proportion of negative urine drug screen results will be significantly greater in the subjects treated with aripiprazole than in those treated with perphenazine.
Secondary outcome measures
The mean cocaine craving scores will be lower in subjects treated with aripiprazole than in those treated with perphenazine.
The mean total self-report cocaine use days will be significantly fewer in subjects treated with aripiprazole than in those treated with perphenazine.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: 1Experimental Treatment1 Intervention
Group II: 2Active Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aripiprazole
FDA approved

Find a Location

Who is running the clinical trial?

Paul SaengerLead Sponsor
1 Previous Clinical Trials
50 Total Patients Enrolled
Thomas P Beresford, MDPrincipal InvestigatorDenver Veteran's Affairs Medical Center
1 Previous Clinical Trials
50 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
Paul Saenger 2008. "A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00737256.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top